"Voyager Therapeutics Skyrockets on $1.2B Novartis Gene Therapy Collaboration"
TL;DR Summary
Voyager Therapeutics' shares surged 35% after announcing a licensing deal with Novartis worth $1.2 billion, including $100 million upfront. The deal grants Novartis access to Voyager's RNA-based screening platform to develop a gene therapy for Huntington's disease, with Voyager eligible for milestone payments and royalties on sales.
- Voyager Therapeutics shares jump after $1.2 billion deal with Novartis Yahoo Finance
- VYGR Stock Catapults Higher After Novartis Sweetens Its Gene Therapy Deal Investor's Business Daily
- Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies GlobeNewswire
- Novartis signs gene therapy deal with Voyager for $100 mln upfront Reuters
- Novartis, Voyager launch $100M gene therapy mission FierceBiotech
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
55%
104 → 47 words
Want the full story? Read the original article
Read on Yahoo Finance